XML 82 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Aggregate Acquisition Consideration (Details) - XIIDRA® And Certain Other Ophthalmology Assets Acquisition - Bausch + Lomb
$ in Millions
Sep. 29, 2023
USD ($)
Business Acquisition [Line Items]  
Cash consideration paid to Novartis at closing, per the Acquisition Agreement $ 1,750
Estimated fair value of contingent consideration 3
Aggregate purchase consideration $ 1,753